Mizuho began coverage on shares of Viveve Medical, Inc. (NASDAQ:VIVE) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $10.00 price objective on the stock.

Several other research analysts also recently commented on the company. Cowen and Company set a $11.00 target price on Viveve Medical and gave the stock a buy rating in a research note on Monday, October 23rd. ValuEngine downgraded Viveve Medical from a sell rating to a strong sell rating in a research note on Monday, August 14th. Finally, Maxim Group reissued a buy rating and set a $11.00 target price on shares of Viveve Medical in a research note on Friday, August 11th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Viveve Medical presently has an average rating of Buy and a consensus price target of $10.40.

Viveve Medical (VIVE) traded up $0.17 during mid-day trading on Thursday, reaching $4.98. The company had a trading volume of 119,334 shares, compared to its average volume of 208,140. Viveve Medical has a fifty-two week low of $3.75 and a fifty-two week high of $11.16. The company has a debt-to-equity ratio of 2.72, a current ratio of 3.89 and a quick ratio of 3.63.

Viveve Medical (NASDAQ:VIVE) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.08). The company had revenue of $4.07 million during the quarter, compared to analyst estimates of $4.10 million. Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. The firm’s revenue for the quarter was up 120.1% compared to the same quarter last year. During the same period last year, the firm earned ($0.46) EPS. sell-side analysts predict that Viveve Medical will post -2 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.watchlistnews.com/mizuho-begins-coverage-on-viveve-medical-inc-vive/1714035.html.

In other news, CFO Scott Durbin purchased 5,000 shares of Viveve Medical stock in a transaction dated Wednesday, August 23rd. The shares were bought at an average cost of $5.25 per share, for a total transaction of $26,250.00. Following the completion of the acquisition, the chief financial officer now owns 11,568 shares in the company, valued at approximately $60,732. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 35.10% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. Rhumbline Advisers bought a new stake in shares of Viveve Medical during the second quarter worth about $110,000. JPMorgan Chase & Co. bought a new stake in Viveve Medical in the second quarter valued at approximately $151,000. Virtu KCG Holdings LLC bought a new stake in Viveve Medical in the second quarter valued at approximately $169,000. Schwab Charles Investment Management Inc. bought a new stake in Viveve Medical in the second quarter valued at approximately $189,000. Finally, California State Teachers Retirement System bought a new stake in Viveve Medical in the second quarter valued at approximately $190,000. Institutional investors own 65.55% of the company’s stock.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.